Clinical Trials in New York

Showing 14861-14880 of 22,668 trials

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

NCT00909363

The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.

Wiskott-Aldrich SyndromeThrombocytopeniaBleeding

Weill Medical College of Cornell University24 participantsStarted Jun 2009

New York, New York, United States

COMPLETEDPhase 2< 1 mile

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018

The purpose of this study is to further evaluate the effects that eltrombopag (and romiplostim) have on platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is being further studied by GlaxoSmithKline (now Novartis) in other conditions associated with low platelets. This research study is being done because eltrombopag has been shown to increase platelet counts in a different way than other therapies for ITP. The investigators want to further study how eltrombopag and romiplostim affect subjects and their platelets to determine how the study drug should best be used in ITP treatment.

Immune Thrombocytopenia

Weill Medical College of Cornell University20 participantsStarted Jan 2009

New York, New York, United States

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Find Trials by Condition in New York

Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation

Get Ready And Empowered About Treatment

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

Clinical Validation of New Commercial Sleep Monitoring Devices

Assessing Cirrhosis Quality of Care While Accounting for Cost

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Evaluating Alcohol Use in Alcoholic Liver Disease

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Rifaximin to Modify the Disease Course in Sickle Cell Disease

A Phase 1 Study in Patients With Solid Tumors

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Driveline Silicone Skin Interface Registry

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)

Moderate Alcohol and Cardiovascular Health Trial

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis